Meeting
2012 ASCO Annual Meeting
CYP2D6 genotype and adverse effects as indicators of plasma endoxifen in breast cancer patients taking tamoxifen.
Authors
Bavanthi Balakrishnar
Westmead Hospital, University of Sydney, Sydney, Australia
Bavanthi Balakrishnar , Alexander M. Menzies , Sayed Sahanawaz Ali , Shang Heng Yeap , Bo Gao , Chris Liddle , Sally Coulter , Pamela Provan , Val Gebski , Rina Hui , Richard Kefford , Nicholas Wilcken , Rosemary L Balleine , Howard Gurney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT01075802
Citation
J Clin Oncol 30, 2012 (suppl; abstr 550)
DOI
10.1200/jco.2012.30.15_suppl.550
Abstract #
550
Poster Bd #
3A
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Simplified CYP2D6 metabolizer phenotype categorization of patients treated with tamoxifen: Role for endoxifen level monitoring?
First Author: Clara Inkyung Lee
Poster
2016 ASCO Annual Meeting
Comparison of endoxifen levels between male and female breast cancer patients treated with tamoxifen.
First Author: John Gordon Lenehan
Poster
2013 ASCO Annual Meeting
Factors predicting endoxifen levels in breast cancer patients taking standard-dose tamoxifen and following dose escalation.
First Author: Peter Fox
Poster
2013 ASCO Annual Meeting
Effect of PK-guided tamoxifen dose escalation on endoxifen serum concentrations in CYP2D6 intermediate and poor metabolizers.
First Author: Frans Opdam